Vanta Bioscience Peer Comparison

BSE: 540729

₹19.64

₹-1.03 (-4.98%)

As on 13-Aug-2026IST

Market cap

₹14 Cr

Revenue (TTM)

₹2 Cr

P/E Ratio

129.3

P/B Ratio

1

Div. Yield

0 %

Edit

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	14	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	2	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-13.29	414.00	288.22	-371.81	387.35
Net Margin (%)	-640.68	11.23	14.79	-3.93	26.01
RoE (%)	-103.74	8.38	29.77	-3.85	25.18
Price to Earnings	129.33	78.49	103.71	--	69.57
Price-To-Book	0.97	6.38	22.27	3.64	15.55

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1.96	3,012.00	1,284.27	9,151.18	1,006.88
Total Income	2.07	3,074.00	1,296.22	9,312.95	1,023.80
Total Expenditure	6.22	2,619.00	1,028.33	7,733.31	774.80
EBITDA	-4.26	393.00	255.95	1,417.87	232.07
Depreciation	4.42	217.00	36.59	816.34	26.62
EBIT	-8.67	176.00	219.36	601.53	205.45
Interest	4.07	254.00	36.78	421.59	6.22
Other Income	0.11	62.00	11.95	161.77	16.93
Exceptional Items	--	--	--	--	--
Profit before Tax	-12.63	-16.00	194.52	414.64	216.16
Provision for Tax	0.66	41.00	60.16	323.51	55.75
Profit after Tax	-13.29	-57.00	134.36	91.13	160.42

Liabilities (₹ Cr)

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	10.42	4,353.00	540.98	8,125.47	1,309.63
Minority Interest	-6.64	304.00	0.00	--	10.45
Non-Current Liabilities	55.53	887.00	122.65	3,392.72	26.93
Current Liabilities	26.56	2,042.00	786.03	3,850.56	202.25
Total Liabilities	85.88	8,100.00	1,451.43	15,513.53	1,549.26

Assets (₹ Cr)

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	70.52	5,017.00	386.29	9,487.47	757.63
Current Assets	15.36	2,465.00	1,063.37	5,881.28	791.64
Total Assets	85.88	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	70.08	1,859.00	393.17	4,720.27	8.18
Net Current Assets	-11.21	423.00	277.34	2,030.72	589.39
Contingent Liabilities	--	770.26	12.25	99.76	15.38

Cashflow (₹ Cr)

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-2.41	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-6.69	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	9.16	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	0.06	-396.00	54.56	-25.99	155.52

Ratios

Profitability Ratios

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-10.93	4.07	26.97	6.61	20.14
ROE (%)	-103.74	-1.48	30.68	1.14	16.19
ROA (%)	-15.52	-0.78	10.50	0.60	12.13
EBIT Margin (%)	-211.14	15.11	20.86	17.26	24.73
Net Margin (%)	-640.68	-1.85	10.37	0.98	15.67
Cash Profit Margin (%)	-451.95	4.14	7.13	8.54	18.58

Growth Ratios

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-79.80	7.65	50.40	11.99	40.34
EBIT Growth (%)	-392.11	272.95	54.77	15.16	83.12
Net Profit Growth (%)	-54.42	87.92	47.63	411.39	229.35
EPS Growth (%)	-106.18	90.35	45.69	410.84	67.16
Book Value Growth (%)	-31.42	29.77	42.49	2.28	94.96

Valuation Ratios

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	0.00	0.00	326.26	62.97
Price / Book Value	1.34	5.31	0.00	3.69	15.26
Dividend Yield (%)	0.00	0.00	--	0.06	0.06
EV/EBITDA	-20.22	54.36	1.09	21.49	79.31
Market Cap (₹ Cr)	13.96	23,064.69	0.00	29,731.27	19,988.69

Solvency Ratios

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	6.72	0.43	0.76	0.59	0.01
Short term debt to equity ratio	0.80	0.11	0.54	0.12	0.01
Current Ratio	0.58	1.21	1.35	1.53	3.91
Quick Ratio	0.33	0.85	0.69	0.93	3.02
Interest Coverage	-2.10	0.94	6.29	1.98	35.76

Operating Efficiency Ratios

	Vanta Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	127.48	21.95	25.21	25.67	28.85
Asset Turnover	0.02	0.53	1.87	0.70	0.76
Receivable days	524.58	60.36	47.59	77.05	90.06
Inventory Days	1,303.78	64.42	62.58	77.13	61.02
Payable days	1,437.15	218.94	228.78	173.49	96.06
Cash Conversion Cycle	391.21	-94.15	-118.62	-19.30	55.02